MEA Uterine Cancer Drug Market - Industry Trends and Forecast to 2033

Description

List of Tables

The Middle East and Africa uterine cancer drugs market is expected to reach USD 113,620.14 million by 2030 from USD 81,299.13 million in 2022, growing at a CAGR of 4.8% during the forecast period of 2023 to 2030.

Market Segmentation

Middle East and Africa Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, and rest of Middle East And Africa) - Industry Trends and Forecast to 2030.

Overview of Middle East and Africa Uterine Cancer Drugs Market Dynamics

Driver
Rising incidence of uterine cancer worldwide
Restraint
High cost of uterine cancer treatment
Opportunity
Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the Middle East and Africa uterine cancer drugs market are listed below:

Baxter
Eli Lilly and Company
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd.
Fresenius SE & Co. KGaA
Viatris Inc.
Sanofi
Teva Pharmaceuticals USA, Inc.
Merck & Co., Inc.
GSK plc.
Eisai Co., Ltd.
Pfizer Inc.
Getwell Oncology

1 INTRODUCTION 19

1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET 19
1.4 LIMITATIONS 21
1.5 MARKETS COVERED 21

2 MARKET SEGMENTATION 24

2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 DBMR TRIPOD DATA VALIDATION MODEL 27
2.6 MULTIVARIATE MODELLING 30
2.7 CANCER TYPE LIFELINE CURVE 30
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.9 DBMR MARKET POSITION GRID 32
2.10 MARKET END USER COVERAGE GRID 33
2.11 VENDOR SHARE ANALYSIS 34
2.12 SECONDARY SOURCES 35
2.13 ASSUMPTIONS 35

3 EXECUTIVE SUMMARY 36

4 PREMIUM INSIGHTS 39

4.1 PESTEL'S MODEL 40
4.2 PORTER'S 5 FORCES 41
4.3 EPIDEMIOLOGY 42

5 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK 43

5.1 OVERVIEW 43
5.2 REGULATION IN THE U.S. 44
5.3 REGULATION IN CANADA 44
5.4 REGULATION IN EUROPE 44
5.5 REGULATION IN CHINA 44
5.6 REGULATION IN JAPAN 44
5.7 REGULATION IN AUSTRALIA 45
5.8 REGULATION IN INDIA 45
5.9 REGULATION IN BRAZIL 45
5.10 REGULATION IN SOUTH AFRICA 45

6 MARKET OVERVIEW 46

6.1 DRIVERS 48
- 6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE 48
- 6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER 49
- 6.1.3 RISING AWARENESS OF UTERINE CANCER 50
- 6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS 51
6.2 RESTRAINTS 52
- 6.2.1 HIGH COST OF UTERINE CANCER TREATMENT 52
- 6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS 53
6.3 OPPORTUNITIES 54
- 6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY 54
- 6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT 55
6.4 CHALLENGES 56
- 6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET 56
- 6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER 57

7 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE 59

7.1 OVERVIEW 60
7.2 ENDOMETRIAL CANCER 63
- 7.2.1 UTERINE CARCINOSARCOMA 64
- 7.2.2 SEROUS ADENOSARCOMA 64
- 7.2.3 ADENOSQUAMOUS CARCINOMA 64
- 7.2.4 OTHER 64
7.3 UTERINE SARCOMA 65
- 7.3.1 UTERINE LEIOMYOSARCOMA 65
- 7.3.2 ENDOMETRIAL STROMAL SARCOMAS 65
- 7.3.3 UNDIFFERENTIATED SARCOMA 66

8 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE 67

8.1 OVERVIEW 68
8.2 CHEMOTHERAPY 71
- 8.2.1 PACLITAXEL 72
- 8.2.2 CARBOPLATIN 72
- 8.2.3 CISPLATIN 72
- 8.2.4 DOXORUBICIN 72
- 8.2.5 DOCETAXEL 72
- 8.2.6 OTHERS 72
8.3 IMMUNOTHERAPY 73

8.4 HORMONE THERAPY 73
- 8.4.1 PROGESTINS 74
  - 8.4.1.1 MEDROXYPROGESTERONE ACETATE 74
  - 8.4.1.2 OTHERS 74
- 8.4.2 AROMATASE INHIBITORS 75
  - 8.4.2.1 LETRAZOLE 75
  - 8.4.2.2 ANASTRAZOLE 75
  - 8.4.2.3 EXEMESTANE 75
- 8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS 76
  - 8.4.3.1 GOSERELIN 76
  - 8.4.3.2 LEUPROLIDE 76
- 8.4.4 OTHERS 76
8.5 TARGETED THERAPY 77
- 8.5.1 LENVATINAB 77
- 8.5.2 BEVACIZUMAB 77
- 8.5.3 MTOR INHIBITORS 77
  - 8.5.3.1 EVEROLIMUS 78
  - 8.5.3.2 TEMSIROLIMUS 78
8.6 OTHERS 78

9 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE 79

9.1 OVERVIEW 80
9.2 GENERICS 83
9.3 BRANDED 83
- 9.3.1 KEYTRUDA 84
- 9.3.2 LENVIMA 84
- 9.3.3 PROVERA 85
- 9.3.4 TEMODAR 85
- 9.3.5 JEMPERLI 85
- 9.3.6 OTHERS 85

10 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP 86

10.1 OVERVIEW 87
10.2 GERIATRIC 90
10.3 ADULTS 90

11 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 91

11.1 OVERVIEW 92
11.2 PARENTERAL 95
11.3 ORAL 95

12 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER 96

12.1 OVERVIEW 97
12.2 HOSPITALS 100
- 12.2.1 PRIVATE 100
- 12.2.2 PUBLIC 100
12.3 CANCER CENTERS 101
12.4 SPECIALTY CLINICS 101
12.5 OTHERS 102

13 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 103

13.1 OVERVIEW 104
13.2 DIRECT TENDER 107
13.3 RETAIL SALES 107
- 13.3.1 HOSPITAL PHARMACY 108
- 13.3.2 RETAIL PHARMACY 108
- 13.3.3 ONLINE PHARMACY 108
13.4 OTHERS 109

14 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY REGION 110

14.1 MIDDLE EAST AND AFRICA 113
- 14.1.1 SAUDI ARABIA 119
- 14.1.2 U.A.E. 124
- 14.1.3 SOUTH AFRICA 129
- 14.1.4 EGYPT 134
- 14.1.5 KUWAIT 139
- 14.1.6 REST OF MIDDLE EAST AFRICA 144

15 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE 145

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 145

16 SWOT ANALYSIS 146

17 COMPANY PROFILES 147

17.1 MERCK & CO., INC. 147
- 17.1.1 COMPANY SNAPSHOT 147
- 17.1.2 REVENUE ANALYSIS 147
- 17.1.3 COMPANY SHARE ANALYSIS 148
- 17.1.4 PRODUCT PORTFOLIO 148
- 17.1.5 RECENT DEVELOPMENT 149

17.2 EISAI CO., LTD. 150
- 17.2.1 COMPANY SNAPSHOT 150
- 17.2.2 REVENUE ANALYSIS 150
- 17.2.3 COMPANY SHARE ANALYSIS 151
- 17.2.4 PRODUCT PORTFOLIO 151
- 17.2.5 RECENT DEVELOPMENT 151
- 17.2.6 RECENT DEVELOPMENT 152
17.3 SANOFI 153
- 17.3.1 COMPANY SNAPSHOT 153
- 17.3.2 REVENUE ANALYSIS 153
- 17.3.3 COMPANY SHARE ANALYSIS 154
- 17.3.4 PRODUCT PORTFOLIO 154
- 17.3.5 RECENT DEVELOPMENT 155
17.4 PFIZER INC. 156
- 17.4.1 COMPANY SNAPSHOT 156
- 17.4.2 REVENUE ANALYSIS 156
- 17.4.3 COMPANY SHARE ANALYSIS 157
- 17.4.4 PRODUCT PORTFOLIO 157
- 17.4.5 RECENT DEVELOPMENT 159
17.5 TEVA PHARMACEUTICALS USA, INC. 160
- 17.5.1 COMPANY SNAPSHOT 160
- 17.5.2 REVENUE ANALYSIS 160
- 17.5.3 PRODUCT PORTFOLIO 161
- 17.5.4 RECENT DEVELOPMENT 161
17.6 ACCORD HEALTHCARE US. 162
- 17.6.1 COMPANY SNAPSHOT 162
- 17.6.2 PRODUCT PORTFOLIO 162
- 17.6.3 RECENT DEVELOPMENT 162
17.7 AMNEAL PHARMACEUTICALS LLC 163
- 17.7.1 COMPANY SNAPSHOT 163
- 17.7.2 REVENUE ANALYSIS 163
- 17.7.3 PRODUCT PORTFOLIO 164
- 17.7.4 RECENT DEVELOPMENT 164
17.8 BAXTER 165
- 17.8.1 COMPANY SNAPSHOT 165
- 17.8.2 REVENUE ANALYSIS 165
- 17.8.3 COMPANY SHARE ANALYSIS 166
- 17.8.4 PRODUCT PORTFOLIO 166
- 17.8.5 RECENT DEVELOPMENT 166

17.9 ELI LILLY AND COMPANY 167
- 17.9.1 COMPANY SNAPSHOT 167
- 17.9.2 REVENUE ANALYSIS 168
- 17.9.3 PRODUCT PORTFOLIO 168
- 17.9.4 RECENT DEVELOPMENT 169
17.10 GETWELL ONCOLOGY 170
- 17.10.1 COMPANY SNAPSHOT 170
- 17.10.2 PRODUCT PORTFOLIO 170
- 17.10.3 RECENT DEVELOPMENT 173
17.11 GSK PLC. 174
- 17.11.1 COMPANY SNAPSHOT 174
- 17.11.2 REVENUE ANALYSIS 174
- 17.11.3 PRODUCT PORTFOLIO 175
- 17.11.4 RECENT DEVELOPMENT 175
17.12 HIKMA PHARMACEUTICALS PLC 176
- 17.12.1 COMPANY SNAPSHOT 176
- 17.12.2 REVENUE ANALYSIS 176
- 17.12.3 PRODUCT PORTFOLIO 177
- 17.12.4 RECENT DEVELOPMENT 177
17.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 178
- 17.13.1 COMPANY SNAPSHOT 178
- 17.13.2 REVENUE ANALYSIS 178
- 17.13.3 PRODUCT PORTFOLIO 179
- 17.13.4 RECENT DEVELOPMENT 179
17.14 VIATRIS INC. 180
- 17.14.1 COMPANY SNAPSHOT 180
- 17.14.2 REVENUE ANALYSIS 180
- 17.14.3 PRODUCT PORTFOLIO 181
- 17.14.4 RECENT DEVELOPMENT 181
17.15 VIRTUS 182
- 17.15.1 COMPANY SNAPSHOT 182
- 17.15.2 PRODUCT PORTFOLIO 182
- 17.15.3 RECENT DEVELOPMENT 182

18 QUESTIONNAIRE 183

19 RELATED REPORTS 187

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND) 62
TABLE 2 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 63
TABLE 3 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 64
TABLE 4 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 5 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 6 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 70
TABLE 7 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 71
TABLE 8 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 71
TABLE 9 MIDDLE EAST AND AFRICA IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 10 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 11 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 74
TABLE 12 MIDDLE EAST AND AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 74
TABLE 13 MIDDLE EAST AND AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 75
TABLE 14 MIDDLE EAST AND AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 76
TABLE 15 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 16 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 77
TABLE 17 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 78
TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 19 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 82
TABLE 20 MIDDLE EAST AND AFRICA GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 21 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 22 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 84
TABLE 23 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND) 89
TABLE 24 MIDDLE EAST AND AFRICA GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 25 MIDDLE EAST AND AFRICA ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 26 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 94
TABLE 27 MIDDLE EAST AND AFRICA PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 28 MIDDLE EAST AND AFRICA ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 29 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND) 99
TABLE 30 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 31 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 100
TABLE 32 MIDDLE EAST AND AFRICA CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
TABLE 35 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND) 106
TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
TABLE 37 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
TABLE 38 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 108
TABLE 39 MIDDLE EAST AND AFRICA OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 109
TABLE 40 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 113
TABLE 41 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 42 MIDDLE EAST AND AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 43 MIDDLE EAST AND AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 44 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 45 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 114
TABLE 46 MIDDLE EAST AND AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 47 MIDDLE EAST AND AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 115
TABLE 48 MIDDLE EAST AND AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 115
TABLE 49 MIDDLE EAST AND AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 115
TABLE 50 MIDDLE EAST AND AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 51 MIDDLE EAST AND AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 116
TABLE 52 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 53 MIDDLE EAST AND AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 116
TABLE 54 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 117
TABLE 55 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 117
TABLE 56 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
TABLE 57 MIDDLE EAST AND AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 58 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 59 MIDDLE EAST AND AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 60 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 61 SAUDI ARABIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 62 SAUDI ARABIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 63 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 64 SAUDI ARABIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 65 SAUDI ARABIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 66 SAUDI ARABIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 67 SAUDI ARABIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 68 SAUDI ARABIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 69 SAUDI ARABIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 70 SAUDI ARABIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 121
TABLE 71 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 72 SAUDI ARABIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 122
TABLE 73 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 122
TABLE 74 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 122
TABLE 75 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 122
TABLE 76 SAUDI ARABIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 77 SAUDI ARABIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 123
TABLE 78 SAUDI ARABIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 79 U.A.E. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 80 U.A.E. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 81 U.A.E. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 82 U.A.E. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 83 U.A.E. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 84 U.A.E. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 85 U.A.E. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 86 U.A.E. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 87 U.A.E. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 88 U.A.E. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 89 U.A.E. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 90 U.A.E. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 91 U.A.E. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 127
TABLE 92 U.A.E. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 127
TABLE 93 U.A.E. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
TABLE 94 U.A.E. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 95 U.A.E. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 96 U.A.E. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
TABLE 97 U.A.E. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 98 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 99 SOUTH AFRICA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 100 SOUTH AFRICA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 101 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 102 SOUTH AFRICA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 103 SOUTH AFRICA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 104 SOUTH AFRICA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 105 SOUTH AFRICA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 106 SOUTH AFRICA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 107 SOUTH AFRICA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 108 SOUTH AFRICA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 131
TABLE 109 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 110 SOUTH AFRICA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 132
TABLE 111 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 132
TABLE 112 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
TABLE 113 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
TABLE 114 SOUTH AFRICA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 115 SOUTH AFRICA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 116 SOUTH AFRICA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 117 EGYPT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 118 EGYPT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 119 EGYPT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 120 EGYPT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 121 EGYPT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 122 EGYPT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 123 EGYPT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 124 EGYPT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 125 EGYPT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 126 EGYPT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 127 EGYPT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 128 EGYPT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 129 EGYPT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 136
TABLE 130 GYPT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 137
TABLE 131 EGYPT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 137
TABLE 132 EGYPT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 133 EGYPT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 134 EGYPT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 135 EGYPT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 136 KUWAIT UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 137 KUWAIT ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 138 KUWAIT UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 139 KUWAIT UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 140 KUWAIT CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 141 KUWAIT HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 142 KUWAIT PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 143 KUWAIT AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 144 KUWAIT LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 145 KUWAIT TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 146 KUWAIT MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 147 KUWAIT UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 148 KUWAIT BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 141
TABLE 149 KUWAIT UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 142
TABLE 150 KUWAIT UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 142
TABLE 151 KUWAIT UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 142
TABLE 152 KUWAIT HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 153 KUWAIT UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 142
TABLE 154 KUWAIT RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 155 REST OF MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 144

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: SEGMENTATION 24
FIGURE 2 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION 27
FIGURE 3 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: DROC ANALYSIS 28
FIGURE 4 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS 29
FIGURE 5 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 29
FIGURE 6 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 31
FIGURE 7 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 32
FIGURE 8 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 33
FIGURE 9 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS 34
FIGURE 10 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: SEGMENTATION 38
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 39
FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030 39
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET 47
FIGURE 14 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022 60
FIGURE 15 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND) 61
FIGURE 16 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 61
FIGURE 17 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE 62
FIGURE 18 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022 68
FIGURE 19 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 69
FIGURE 20 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 69
FIGURE 21 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 70
FIGURE 22 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022 80
FIGURE 23 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND) 81
FIGURE 24 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 81
FIGURE 25 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 82
FIGURE 26 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY TYPE, 2022 87
FIGURE 27 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND) 88
FIGURE 28 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 88
FIGURE 29 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 89
FIGURE 30 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 92
FIGURE 31 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 93
FIGURE 32 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 93
FIGURE 33 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 94
FIGURE 34 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY END USER, 2022 97
FIGURE 35 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND) 98
FIGURE 36 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 98
FIGURE 37 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 99
FIGURE 38 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 104
FIGURE 39 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 105
FIGURE 40 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 105
FIGURE 41 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 106
FIGURE 42 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022) 111
FIGURE 43 MIDDLE EAST AND AFRICA UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 145